Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) is the most serious and prevalent neurodegenerative disorder still without cure. Since its aetiology is diverse, recent research on anti-AD drugs has been focused on multi-target compounds. In this work, seven novel hybrids (RIV–BIM) conjugating the active moiety of the drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Vicente-Zurdo, David, Rosales-Conrado, Noelia, León-González, M. Eugenia, Brunetti, Leonardo, Piemontese, Luca, Pereira-Santos, A. Raquel, Cardoso, Sandra M., Madrid, Yolanda, Chaves, Sílvia, Santos, M. Amélia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313321/
https://www.ncbi.nlm.nih.gov/pubmed/35884815
http://dx.doi.org/10.3390/biomedicines10071510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313321/
https://www.ncbi.nlm.nih.gov/pubmed/35884815
http://dx.doi.org/10.3390/biomedicines10071510

Ejemplares similares